Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Fuji
QuintilesIMS
McKesson
Merck
Boehringer Ingelheim
Deloitte
Accenture
Queensland Health

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

« Back to Dashboard

Clinical Trials for Benazepril Hydrochloride And Hydrochlorothiazide

Trial ID Title Status Sponsor Phase Summary
NCT00170950 Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension Terminated Novartis Phase 3 A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
NCT00367094 Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension Completed Novartis Phase 3 This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day.
NCT00649038 Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg Completed Mylan Pharmaceuticals Phase 1 The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fed conditions.
NCT00649597 Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg Completed Mylan Pharmaceuticals Phase 1 The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fasting conditions.
NCT00778674 Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions Completed Ranbaxy Laboratories Limited N/A The purpose of this study was to determine the bioavailability of Benazepril and hydrochlorothiazide (HCTZ) from two Benazepril/HCTZ 20 mg/25 mg products after administration of single doses to normal healthy subjects under fed conditions. These data were to be evaluated statistically to determine if the products meet bioequivalence criteria.
NCT00778726 Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions Completed Ranbaxy Laboratories Limited N/A The purpose of this study was to determine the bioavailability of benazepril and hydrochlorothiazide (HCTZ) from two Benazepril/HCTZ 20 mg/25 mg products after administration of single doses to normal healthy fasted subjects. These data were to be evaluated statistically to determine if the products meet bioequivalence criteria.
NCT01375322 ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria Completed TSH Biopharm Corporation Limited Phase 4 The purpose of the study is to compare the change from baseline in blood pressures (DBP/SBP) to 16-week regimen between Amtrel® and Co-Diovan®. The secondary objectives were listed as the following. - To compare the response rate (defined as SBP < 130 mmHg and DBP < 80 mmHg) at the end of study - To evaluate the change from baseline in albumin-to-creatinine ratio with antihypertensive medications in whole group (combined treatment groups) and each treatment group (Amtrel®, Co-Diovan®) at Week 16 - The change from baseline in glycosylated hemoglobin (HbA1c) at Week 16 - The change from baseline in fasting plasma glucose (FPG) at Week 16 - The change from baseline in fasting lipid profiles (triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol) at Week 16 - The change from baseline in arteriosclerosis marker (brachial-ankle pulse-wave velocity (ba-PWV) and ankle-brachial pressure index (ABI), using Colin-VP1000) at Week 16 - The change from baseline on the body mass index (BMI) and waist-hip ratio (WHR) at each specified study time point - To ascertain the safety and tolerability of Amtrel® versus Co-Diovan® including AE/SAE, and laboratory examinations
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Benazepril Hydrochloride And Hydrochlorothiazide

Condition Name

Condition Name for Benazepril Hydrochloride And Hydrochlorothiazide
Intervention Trials
Healthy 4
Hypertension 3
Diabetes Mellitus, Type 2 1
Albuminuria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Benazepril Hydrochloride And Hydrochlorothiazide
Intervention Trials
Hypertension 3
Diabetes Mellitus, Type 2 1
Diabetes Mellitus 1
Albuminuria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Benazepril Hydrochloride And Hydrochlorothiazide

Trials by Country

Trials by Country for Benazepril Hydrochloride And Hydrochlorothiazide
Location Trials
United States 5
Norway 1
China 1
Finland 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Benazepril Hydrochloride And Hydrochlorothiazide
Location Trials
North Carolina 2
North Dakota 2
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Benazepril Hydrochloride And Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Benazepril Hydrochloride And Hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 1 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Benazepril Hydrochloride And Hydrochlorothiazide
Clinical Trial Phase Trials
Completed 6
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Benazepril Hydrochloride And Hydrochlorothiazide

Sponsor Name

Sponsor Name for Benazepril Hydrochloride And Hydrochlorothiazide
Sponsor Trials
Ranbaxy Laboratories Limited 2
Mylan Pharmaceuticals 2
Novartis 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Benazepril Hydrochloride And Hydrochlorothiazide
Sponsor Trials
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cipla
Johnson and Johnson
Healthtrust
QuintilesIMS
Merck
McKinsey
Colorcon
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.